Attending European Renal Association (ERA)’s Congress this May? We’ll be sharing oral presentations with data on our investigational agent felzartamab including interim results from the Phase 2 IGNAZ study results in IgA nephropathy (IgAN) and Phase 2 investigator-sponsored study results in antibody-mediated rejection (AMR) in kidney transplant recipients. See the more details about our abstracts here: https://lnkd.in/e9V85DFB
HI-Bio: A Biogen Company’s Post
More Relevant Posts
-
Excited to present at ASN Kidney Week 2023 (2nd Nov) on our Mission Therapeutics abstract titled "MTX652, a Novel Selective USP30 Inhibitor for the Treatment of Acute Kidney Injury (AKI): Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections." I'd be very happy to catch up with colleagues there, so let me know if you are attending! #ASNKidneyWeek2023 #MTX652 #AKI #ClinicalTrial #MissionTherapeutics
To view or add a comment, sign in
-
Modified pancreaticoduodenectomy: A viable alternative to hepatopancreaticoduodenectomy for middle-third cholangiocarcinoma by Onoe S, Mizuno T (...) Ebata T et 7 al. in HPB (Oxford)
Utility of modified pancreaticoduodenectomy (Hi-cut PD) for middle-third cholangiocarcinoma: an alternative to hepatopancreaticoduodenectomy
hpbonline.org
To view or add a comment, sign in
-
For all my #raredisease followers.. The FDA just approved #Winrevair (sotatercept-csrk) for #PAH. Winrevair was tested as an adjunct to established dual or triple PAH therapy. Most of its side effects were hematologic, including thrombocytopenia and increased haemoglobin. Current therapies for PAH include vasodilators, and treatments that address smooth muscle cell overgrowth, inflammation, and platelet aggregation. Unique from other current vasodilators approved for the condition, Winrevair appears to directly reduce MAP without increasing cardiac output. Winrevair is an activin signaling inhibitor. It is given SQ once every 3 weeks. Like prostacyclin therapy, Winrevair has reproductive impacts. For a crash course on the latest in PAH, check out this review: 10.3390/ijms24043332
To view or add a comment, sign in
-
The role of octreotide on renal function in patients with advanced cirrhosis #EurekaMag
The role of octreotide on renal function in patients with advanced cirrhosis
eurekamag.com
To view or add a comment, sign in
-
Dupilumab: VOYAGE of discovery leading to a further EXCURSION https://lnkd.in/ef9aQJfh
Dupilumab: VOYAGE of discovery leading to a further EXCURSION
thelancet.com
To view or add a comment, sign in
-
#PRESS: The Indian drug regulatory authority has approved Jardiance® (empagliflozin) 10mg tablets to reduce the risk of sustained decline in eGFR (only for patients with eGFR 30-90 ml/min/1.73sqm), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. This indication approval allows the nephrologists and cardiologists to use Jardiance 10mg tablets for the treatment of CKD in the eligible patients and help relieve burden on healthcare systems by reducing the risk of hospitalizations, as well as delaying progression to kidney-failure that necessitates dialysis or kidney transplantation. At Boehringer Ingelheim, we are solemnly committed to transforming lives of the patients, by bringing innovative therapies to help our physicians, optimally address the medical needs of our country! Learn more about it here https://lnkd.in/eADYqMtH #Kidneydisease #HealthcareInnovation
To view or add a comment, sign in
-
-
Dupilumab: VOYAGE of discovery leading to a further EXCURSION https://lnkd.in/eKmbMTuk
Dupilumab: VOYAGE of discovery leading to a further EXCURSION
thelancet.com
To view or add a comment, sign in
-
Finally. Hopefully this is truly transformative. As Karin points out both in terms of “xenotransplantation” per se and the introduction of “novel immunomodulators”.
President at Lyfebulb, Chief Medical Officer, Patient Care America, Health care executive, Patient leader, Independent board member
Amazing news for patients and the transplant field in general! It is about time we see something new and here we have both xeno and novel immune modulators in play. Currently 20 people die each day on the list and many more are not even eligible for transplant, but still in their dialysis chairs. The lack of supply is a huge reason for this tragedy. Eledon Pharmaceuticals, Inc. eGenesis, Inc. Lyfebulb Patient Care America
Recipient of world's first pig kidney transplant discharged from Boston hospital
cbsnews.com
To view or add a comment, sign in
-
The LIPOSORBER team will be in Philadelphia on Nov 2-5 for ASN's Kidney Week Annual Meeting. Make sure to stop by our booth (506) to learn about how treatment with LIPOSORBER has enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.* Ref: Muso, Eri et al. “Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8. *Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years. Based on study that took place over two (2) years. #ASN2023 #kidneywk
To view or add a comment, sign in
-
-
Nephrology towards precision medicine through nucleic acid therapeutics! ERA G&K aims to learn how this changes the landscape of patient care in both PH1 and kidney medicine in general. We would like you to contribute and fill the survey (explicitly NOT only but also for PH1 experts): https://bit.ly/433iqVT
To view or add a comment, sign in
-